Arizona Arthritis & Rheumatology Associates First to Offer SetPoint Therapy in Arizona, Expanding Access to Breakthrough Rheumatoid Arthritis Treatment
The largest rheumatology group in the state treats first rheumatoid arthritis patient with neuroimmune modulation therapy
VALENCIA, Calif. – April 1, 2026 – SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced the first SetPoint System® procedure in Arizona, marking continued expansion of its novel neuroimmune modulation therapy for the treatment of rheumatoid arthritis (RA).
Arizona Arthritis & Rheumatology Associates (AARA), one of the largest rheumatology practices in the United States, treated the first patient with the SetPoint System, the first and only U.S. Food and Drug Administration (FDA)-approved neuroimmune modulation device for adults who do not respond to or cannot tolerate biologic or targeted RA drug therapies.
“Treating the first rheumatoid arthritis patient in Arizona with SetPoint Therapy represents a meaningful step forward in how we approach this autoimmune disease,” said John Tesser, M.D., FACP, FACR, MACR, rheumatologist at AARA and national principal investigator of the RESET-RA study. “This novel, neuromodulation device-based therapy offers a fundamentally new mechanism of action that goes beyond traditional pharmacologic approaches for management of rheumatoid arthritis. We’re proud at AARA to be at the forefront of bringing innovative evidence-based therapies like this to our patients.”
The SetPoint System is an implantable neuroimmune modulation device that stimulates the left vagus nerve for one minute daily to activate innate anti-inflammatory pathways to treat RA. The positive clinical impact of the SetPoint System was detailed in the RESET-RA trial and recently published in Nature Medicine, showing clinically meaningful improvements and sustained efficacy through 12 months, with approximately 50% of participants achieving low disease activity or remission and 75% remaining free of added biologic or targeted RA drugs.1
“Treating the first rheumatoid arthritis patient in Arizona with SetPoint Therapy marks an important milestone in expanding access to this novel neuroimmune approach,” said Murthy Simhambhatla, CEO of SetPoint Medical. “We are proud to partner with forward-thinking clinicians at AARA to advance the standard of care in rheumatoid arthritis.”
The introduction of the SetPoint System in Arizona builds on the company’s commercial momentum, with the therapy now available in cities in New York, Illinois, California, Texas, and Arizona.
About SetPoint System
The SetPoint System is indicated for use in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response, loss of response, or intolerance to one or more biological or targeted synthetic disease modifying antirheumatic drugs. It should not be used if you have had a vagotomy or splenectomy, or if your healthcare provider determines that it is not safe for you to use the SetPoint System. Risks may include, but are not limited to, pain or infection after surgery, hoarseness, bruising, swelling, coughing and throat irritation.
For full safety information, please see Instructions for Use and our Important Safety Information at spm.care/ISI.
Individual results may vary.
About SetPoint Medical
SetPoint Medical is a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases. The company’s FDA-approved SetPoint System is the first neuroimmune modulation therapy available for people living with rheumatoid arthritis (RA), offering a novel, device-based alternative for those who do not respond to or cannot tolerate biologic or targeted drug therapies. SetPoint’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. With a vision to redefine the care of autoimmune conditions, SetPoint is also planning to evaluate its platform technology for other conditions including multiple sclerosis and Crohn’s disease. Learn more at setpointmedical.com.
Dr. John Tesser is a study investigator and consultant for SetPoint Medical. He has not been compensated in connection with this press release.
Media Contact
Maria Bradley
415-509-0498
[email protected]
1 Tesser, J.R.P., Crowley, A.R., Box, E.J. et al. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nat Med 32, 369–378 (2026). https://doi.org/10.1038/s41591-025-04114-7